Joshua Donfeld

First Reserve Management LP (First Reserve) is a private equity firm founded in 1983. The firm is headquartered in Stamford, Connecticut.

Fidelity Management & Research Co. (FMR) is a SEC-registered investment advisor headquartered in Boston, Massachusetts. The firm was founded in 1946 and is a subsidiary of FMR LLC, also known as Fidelity Investments. FMR provides investment supervisory services, which include sub-advisory services, to Fidelity's family of mutual funds and exchange-traded funds, qualified tuition programs, privately offered unregistered investment funds, separately managed account clients, and various other institutional accounts.

Soros Fund Management LLC (SFM) is a privately-held investment management firm now structured as a family office, but which was once a hedge fund manager. The firm was founded in 1969 and is headquartered in New York City. SFM serves as the principal asset manager for the Open Society Foundations (Open Society) – a private funder of independent groups that works for justice, democratic governance, and human rights.

DW Partners LP (DW) is an independent, SEC-registered investment advisor and alternative asset manager headquartered in New York City. The firm was founded by David Warren and Robert Clark in 2009 as DW Investment Management LP and legally changed their name to DW Partners LPin 2014. DW provides discretionary investment management services to private investment funds and separately managed accounts.

Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team.

FFL Partners LLC (FFL) is a private equity firm founded in 1997 by Tully Friedman, Spencer Fleischer, David Lowe, and Christopher Masto. The firm is headquartered in San Francisco, California.

Morgan Stanley & Co. International Plc (MSCI) is a brokerage firm headquartered in London, UK. The firm was founded in 1986 and is a subsidiary of Morgan Stanley Investments (UK), ultimately held by Morgan Stanley (NYSE: MS) in the US. MSCI provides a range of brokerage services to corporations, governments and financial institutions.

Global Infrastructure Management LLC (GIP) is a private equity firm founded in 2006. The firm is headquartered in New York.

BlueCrest Capital Management (New York) LP (BCM) is a hedge fund manager headquartered in New York City. The firm was founded in 1998 and is a subsidiary of BC Capital Management Services Ltd. BCM provides investment advisory and management services to high-net-worth clients.

East West Capital Partners Pte Ltd (East West Capital Partners) is a Private Equity firm founded in 2005 by Sanjay K Sehgal. The firm is headquartered in Singapore.

Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom.

Arlon Group LLC operates as a food and agriculture investment firm. It provides investment across the entire food supply chain. The company was founded in 2007 and is headquartered in New York, NY.

PointState Capital LP is an independent, SEC-registered investment manager and hedge fund manager headquartered in New York City. The firm was founded in 2011 by Joshua Samuelson and Zachary Schreiber. PointState Capital provides discretionary investment advisory services, which include but not limited to, managing and directing the investment and reinvestment of assets for private investment funds and has provided these services to a discretionary separately managed account. Investors in the PointState Funds primarily consist of charitable foundations, institutions, endowments, funds of funds, private or family-owned investment entities, trusts and high net-worth individuals.

Allarity Therapeutics Europe ApS operates as a pharmaceutical company that provides oncology products. The firm engages in diagnostics and drug development. The company was founded by Steen Meier Knudsen on August 1, 2012 and is headquartered in Hørsholm, Denmark.

Braidlock Ltd. engages in the development and manufacture of medical products. Its products include Braidlock Chevron and Braidlock NG. The company was founded in 2004 and is headquartered in Prestwick, the United Kingdom.

Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY.

Part of Healthtech Solutions, Inc., Varian Biopharmaceuticals, Inc. is a private precision oncology company based in Naples, FL. Varian Bio is developing novel therapeutics for the treatment of cancer using precision oncology, which involves DNA testing to identify genetic mutations in tumors for more targeted treatment recommendations. Varian Bio's lead drug candidate, Var-101, is being developed in a topical formulation for the treatment of basal cell carcinoma, while Var-102, an oral formulation, is being developed for the treatment of various solid tumors, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Varian Bio is also seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. The CEO of the company is Jeffrey Blaine Davis. Varian Biopharmaceuticals was acquired by Healthtech Solutions, Inc. on May 07, 2021.